SR12813

SR12813 (GW 485801) is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, with an IC50 value of 0.85 μM[1][2]. SR12813 is also an efficient agonist of human pregnane X receptor (hPXR) . SR12813 can strongly bind to hPXR but not to mouse PXR (mPXR) [3].

Product Specifications

CAS Number

[126411-39-0]

Product Name Alternative

GW 485801

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Autophagy; HMG-CoA Reductase (HMGCR) ; Pregnane X Receptor (PXR)

Type

Reference compound

Related Pathways

Autophagy; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/SR12813.html

Purity

99.80

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

OC1=C(C(C)(C)C)C=C(/C=C(P(OCC)(OCC)=O)/P(OCC)(OCC)=O)C=C1C(C)(C)C

Molecular Formula

C24H42O7P2

Molecular Weight

504.53

Precautions

H302, H315, H319, H335

References & Citations

[1]Berkhout TA, et al. The novel cholesterol-lowering drug SR-12813 inhibits cholesterol synthesis via an increased degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem. 1996 Jun 14;271 (24) :14376-82.|[2]Wei Jiang, et al. Forward genetic screening for regulators involved in cholesterol synthesis using validation-based insertional mutagenesis. PLoS One. 2014 Nov 26;9 (11) :e112632.